Continuous activation of hypoxia-inducible factor (HIF) is important for progression of renal cell carcinoma (RCC) and acquired resistance to anti-angiogenic multi-kinase and mTOR inhibitors. Recently, HIF2α antagonists PT2385 and PT2399 were developed and are being evaluated in a Phase I clinical trial for advanced or metastatic clear cell RCC (ccRCC). However, resistance to HIF2α antagonists would be expected to develop. In this study, we identified signals activated by HIF2α deficiency as candidate mediators of resistance to the multi-kinase inhibitor sunitinib. We established sunitinib-resistant tumor cells in vivo and created HIF2α-deficient variants of these cells using CRISPR/Cas9 technology. Mechanistic investigations revealed that a regulator of the serine biosynthesis pathway, phosphoglycerate dehydrogenase (PHGDH), was upregulated commonly in HIF2α-deficient tumor cells along with the serine biosynthesis pathway itself. Accordingly, treatment with a PHGDH inhibitor reduced the growth of HIF2α-deficient tumor cells in vivo and in vitro by inducing apoptosis. Our findings identify the serine biosynthesis pathway as a source of candidate therapeutic targets to eradicate advanced or metastatic ccRCC resistant to HIF2α antagonists.
INTRODUCTION
In the last decade, molecularly targeted therapeutics, such as anti-angiogenic multityrosine kinase inhibitors (TKIs) or mammalian target of rapamycin (mTOR) inhibitors have been widely used for patients with metastatic or recurrent renal cell carcinoma (RCC) (1) . However, these types of therapies are not expected to have curative effects because they extend progression-free survival only slightly due to acquisition of resistance to these drugs (2) . Therefore, it is necessary to elucidate and overcome the molecular mechanisms of resistance to these drugs.
We previously reported that glucose transporter protein type 1 (GLUT1) and hexokinase-2 (HK2) (3, 4) , which function as key molecules in the glycolytic pathway, are upregulated in clear cell RCC (ccRCC) through suppression of microRNAs targeting GLUT1 or HK2. Similar to many other cancers, RCC is dependent on aerobic glycolysis for ATP production, a phenomenon known as the Warburg effect (5-7); therefore, glucose metabolism to lactate is increased in the presence of sufficient oxygen. However, dysregulation of metabolic pathways occurs when some genes are mutated, allowing cells to avoid the undesirable environment caused by chemotherapy or radiation (8) . Accordingly, developing a deeper understanding of the mechanisms through which ccRCC acquires drug resistance will facilitate the development of novel treatment options for advanced ccRCC. Hypoxia-inducible factor (HIF) is known to accelerate glycolysis, and continuous HIF activation was thought to be critical for RCC progression and acquired resistance to TKIs and mTOR inhibitors (9) . Although HIF2α is thought to be undruggable, HIF2α antagonists (PT2399 and PT2385) are currently being developed (10, 11) . These HIF2α antagonists have been shown to have excellent inhibitory effects against tumours in vivo compared with sunitinib, a TKI and used as a standard first-line therapy for metastatic ccRCC (1) . In addition, PT2399 has also been shown to lead to improved outcomes with regard to progression-free survival in patients with advanced or metastatic ccRCC who had prior TKIs (11) . Although HIF2α antagonists have shown promising potency, ccRCCs requiring long treatment periods with HIF2α antagonists acquired resistance through HIF mutations that prevent PT2399 from entering the cavity or preserve HIF2 dimers due to structural changes (11) . Therefore, improvement of current HIF2α antagonists may be necessary to overcome the effects of structural mutations and achieve better outcomes. All cell lines were tested and found negative for mycoplasma (e-Myco Mycoplasma PCR Detection Kit; iNtRON, Korea). These cell lines were incubated as previously described (15) . Gavage feeding of sunitinib (40 or 25 mg/kg, five times a week; biorbyt, CA, USA) was performed in mice. The tumour sizes and weights were measured and calculated as previously described (15) . The chemical structures of sunitinib is in Supplementary Figure 1A .
CRISPR-Cas9 mediated gene knockout and lentivirus-mediated gene expression
We used CRISPR-Cas9-mediated genome editing to achieve gene knockout with lentiCRISPR v2 (Addgene Plasmid #52961), which was a kind gift from Dr. Feng Zhang. The sgRNAs targeting HIF2α were designed as previously described (15) . The sgRNA sequence, 5′-GCTGATTGCCAGTCGCATGA-3′ or 5′-CAAGGCCTCCATCATGCGAC-3′, which targeted the exon of HIF2α, was cloned into lentiCRISPR v2. For PHGDH overexpression in cells, we used pLJM5-WT PHGDH, which was a gift from Dr. David Sabatini (Addgene plasmid #83901) (14) .
We produce lentivirus as previously described (15) .
Cell proliferation, apoptosis, and colony formation assays CBR-5884 (Focus Biomolecules, Plymouth Meeting, PA, USA) and NCT-503 (Aobious, Gloucester, MA, USA) were used as PHGDH inhibitors (13, 14) . Total RNA was isolated using Isogen (Nippon Gene, Tokyo, Japan) according to the manufacturer's protocol. We applied a SYBR-green quantitative PCR-based array approach as previously described (15) , and the following primers were used: HIF2α, forward primer, 5′-CGGAGGTGTTCTATGAGCTGG-3′ and reverse primer, 5′-AGCTTGTGTGTTCGCAGGAA-3′; and GUSB, forward primer, 5′-CGTCCCACCTAGAATCTGCT-3′ and reverse primer, 5′-TTGCTCACAAAGGTCACAGG-3′. 
RNA sequencing and quantitative proteomics analyses
RNA sequencing was performed by Eurofins Japan. mRNA profiles were generated by single-read deep sequencing using Illumina HiSeq 2500/2000. In vitro proteome-assisted multiple reaction monitoring for protein absolute quantification (iMPAQT) analysis was performed at Kyusyu University in Japan (12) .
Metabolite analysis
Metabolome analysis was performed at Human Metabolome Technologies (HMT, Tsuruoka, Japan, http://humanmetabolome.com). Cellular metabolites were extracted according to the manufacturer's protocol. Metabolome analysis was performed by capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS). Metabolite peaks were quantified and normalised according to protein concentrations.
Immunoassays
Immunoblotting was carried out as previously described (15) Billerica, MA), and anti-β-actin antibodies (bs-0061R; Bioss, Woburn, MA, USA).
Immunohistochemistry were performed using an UltraVision Detection System (Thermo Scientific, Fremont, CA, USA) according to the manufacturer's instructions. The primary rabbit monoclonal antibodies against Ki67 (ab92742; Abcam) were diluted 1:100. For immunofluorescence analyses, nuclei were stained with DAPI (1 μg/mL; Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA), and slides were mounted in Fluoromount (Diagnostic Biosystems, Pleasanton, CA, USA).
Anti-PHGDH antibodies (HPA021241; Sigma) were used as the primary antibody at a dilution of 1:100, and binding was visualised using secondary antibodies conjugated to Alexa Fluor 488 (ab150077; Abcam).
Bioinformatics analysis
The Cancer Genome Atlas (TCGA) cohort database for 534 patients with ccRCC (KIRC) was used for analysis of clinical relevance (16) (17) (18) (19) . Gene set enrichment analysis (GSEA) was performed to identify enriched pathways using open source software v2.0 (www.broad.mit.edu).
Statistical analysis
Statistical analysis was carried out as previously described (15 
RESULTS

Establishment of sunitinib-resistant ccRCC cells
We injected 786-o ccRCC cells into mice subcutaneously and started sunitinib treatment after tumour formation to establish sunitinib-resistant ccRCC cells (Fig. 1A, left) . After tumours acquired resistance to sunitinib, tumours were extracted and harvested. Tumours showing HIF2α expression were selected for subsequent experiments as SU-R-786-o cells (Fig. 1A, right) . We confirmed that SU-R-786-o cells showed resistant to sunitinib compared with parental cells in cell proliferation and xenograft assays (Fig. 1B and 1C ).
HIF2α knockout by CRISPR/Cas9 in SU-R-786-o cells
HIF upregulation was postulated to be associated with resistance to inhibitors of the vascular endothelial growth factor (VEGF) and mTOR pathways (9) . Therefore, we next attempted to knock out HIF2α using the CRISPR/Cas9 system in SU-R-786-o cells, because 786-o parent cell depends more on HIF2α than on HIF1α (10). The expression of HIF2α in HIF2α-KO-SU-R-786-o cells was confirmed by immunoblotting analysis (Fig. 2A) . Known HIF target genes were downregulated in 
HIF2α-KO-SU-R-786-o cells mimicked treatment with the HIF2α antagonist (Fig. 2B) . Surprisingly, HIF2α-KO-SU-R-786-o cells showed dramatic morphological changes from a spindle shape to a round cell shape, whereas no distinct changes were observed in SU-R-786-o cells transduced by empty vector (Fig. 2C) . Cell proliferation was significantly decreased in HIF2α-KO-SU-R-786-o cells compared with that in control cells (Fig. 2D) . (Fig. 3A and 3C) . From the combined RNA sequencing and proteomics analysis, we identified PHGDH (Fig. 3A) . The RNA sequencing and proteomics data were approved by the DNA Data Bank of Japan (DDBJ) with accession number DRA006007, and Japan Proteome Standard Repository/Database (jPOST) with accession number PXD007222, respectively. We also performed pathway analyses with the 141 upregulated genes identified in proteomics analysis; GSEA, GO-BP, and KEGG identified the serine biosynthesis pathway as a (Fig. 3D and Suppl. Fig. 2 ).
Identification of PHGDH in
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Effects of PHGDH inhibition in HIF2α-KO-SU-R-786-o cells
Immunoblotting analyses showed that PHGDH was dramatically elevated in HIF2α-KO-SU-R-786-o cells (Fig. 4A) . Cell proliferation was inhibited by si-PHGDH transfection in HIF2α-KO-SU-R-786-o cells compared to empty cells (Fig. 4B) . We also used two novel PHGDH inhibitors, CBR-5884 and NCT-503, for cell proliferation assays, and found that these compounds showed potent inhibitory effects in HIF2α-KO-SU-R-786-o cells (Fig. 4C and Suppl. Fig. 3A ). In addition, CBR-5884 significantly induced apoptosis in HIF2α-KO-SU-R-786-o cells (Fig. 4D) . We also found its apoptotic effect in ccRCC cell lines, such as A498, ACHN, and Caki1 cells (Suppl. Fig. 3B ). We then performed xenograft assays with NCT-503 because CBR-5884 was unstable in mouse plasma, whereas NCT-503 had been used successfully in prior xenograft assays (13, 14) . We found that tumour growth was significantly suppressed in the mice treated with NCT-503 compared with that in vehicle-treated mice (Fig. 4E) . Immunohistochemistry with Ki67 antibodies indicated that the administration of NCT-503 significantly reduced cell proliferation in HIF2α-KO-SU-R-786-o cells in vivo, relative to vehicles (Fig. 4F) .
Research. 
PHGDH overexpression in ccRCC cells
We overexpressed PHGDH in 786-o and A498 parental cells (Fig. 5A) . As observed following HIF2α knockout in SU-R-786-o cells, 786-o and A498 cells that showed PHGDH strong overexpression exhibited a change in morphology from a spindle shape to a round cell shape (Fig.   5B ). Using immunofluorescence analyses, 786-o cells that showed weak PHGDH overexpression did not show altered cell morphology and still maintained a spindle shape (Fig. 5C , left upper, white arrow, and right). However, 786-o and A498 cells showing strong expression of PHGDH exhibited a homogeneous change in shape to round cells (Fig. 5C ). The number of colonies were significantly increased in PHGDH overexpressed 786-o or A498 cells compared to parental cells (Fig. 5D ).
PHGDH gene amplification was correlated with poor overall survival in ccRCC
According to TCGA database, patients with PHGDH gene amplification (n = 24) had poor overall survival and disease-free survival in comparison to patients without amplification (n = 500; P = 0.0003 and 0.0329, respectively; Fig. 6A) . A multivariate Cox proportional hazards model also showed that PHGDH gene amplification was an independent predictor of overall survival (Fig. 6B and Supplementary Table 1) . We also analysed relationship between PHGDH copy number alteration and Von Hippel-Lindau (VHL) mutation, HIF1A, or HIF2A. There was no significant relationship between PHGDH copy number alteration and VHL mutation (P = 0.491), or HIF1A expression (P = 0.0649) (Suppl. Fig. 4A and 4B) . However, there was a significant negative correlation between PHGDH copy number alteration and EPAS1 (HIF2A) expression (P = 0.0062) (Suppl. Fig. 4B ).
Metabolite analysis in 786-o parent, SU-R-786-o, and HIF2α-KO-SU-R-786-o cells
As shown in the heat map ( and TGF-α, to facilitate angiogenesis, migration, and proliferation through the development of an aggressive phenotype and resistance to chemotherapy and radiation therapy, thereby supporting the metabolic shift that underlies RCC tumourigenicity (8, 20) . While current targeted therapies, including sorafenib, sunitinib, bevacizumab, pazopanib, and axitinib, have targeted the downstream effects of HIF activity, the HIF complex was previously considered "undruggable" (21) . In pVHL-deficient ccRCCs, not HIF1α but HIF2α displayed enhancing proliferation and resistance to replication stress through c-Myc activation (22) . Recently, two studies showed that HIF2α could be targeted by novel inhibitors (10, 11) . Chen et al showed that the novel HIF2α inhibitor PT2399 suppressed tumor growth by 60% across patient-derived ccRCC xenograft (PDX) in 56% of PDX lines; the mechanism of action was shown to require interruption of heterodimer complex with HIF1β and prevention of gene transcription (11) . In addition, they identified HIF mutations that prevented PT2399 from entering the cavity or preserved HIF-2 dimers due to structural changes, thereby contributing to the resistance mechanism. They also referred to the development of second-generation inhibitors and/or complementary approaches, including other potential 
drug-binding pocket inhibitors (23) . Therefore, our results from HIF2α-knockout cells were different from their findings of resistance to PT2399 and may indicate the involvement of a more fundamental mechanism, e.g., PHGDH-based serine production.
Many studies have shown that the serine biosynthesis pathway plays a critical role in various cancers (13, 14, (24) (25) (26) (27) (28) (29) . PHGDH, the first enzyme in serine biosynthesis from glycolysis, is amplified or overexpressed in various types of cancers (28, 29) . In a ccRCC cohort from TCGA database, patients with PHGDH gene amplification had poor overall survival and disease-free survival in comparison to patients without amplification; therefore, PHGDH could be targeted not only for patients showing resistance to HIF2α antagonists but also for patients showing PHGDH gene amplification. TCGA database also showed no significant relationship of PHGDH copy number alteration with VHL mutation, or HIF1A expression but a significant negative correlation of it with EPAS1 (HIF2A) expression. These data may support our finding that expression of PHGDH was revived in HIF2α-knockout cells, on the other hand they might indicate that only PHGDH copy number alteration cannot explain the mechanism underlying RCC develop in the presence of wild type VHL. Recently, PHGDH inhibitors (NCT-503 and CBR-5884) were developed by different laboratories (13, 14) . Although NCT-503 has only been applied for in vivo experiments because of the instability of CBR-5884 in mouse plasma, both inhibitors showed cell inhibitory effects in this 
